<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02897206</url>
  </required_header>
  <id_info>
    <org_study_id>13.06.1.2.30</org_study_id>
    <nct_id>NCT02897206</nct_id>
  </id_info>
  <brief_title>Imipenem Prophylaxis in Patients With Acute Pancreatitis</brief_title>
  <acronym>IMPROWE</acronym>
  <official_title>Imipenem Prophylaxis of Infectious Complications in Patients With Acute Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Rijeka</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rijeka</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Rijeka</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-center, randomized, placebo-controlled, double-blind clinical
      trial that aims to investigate the beneficial and harmful effects of prophylactic use of
      imipenem in patients with predicted severe acute pancreatitis. All patients with first attack
      of acute pancreatitis, an onset of disease less than 72h before admission, and an APACHE II
      score ≥ 8 calculated within the first 24h from admission will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infectious complications</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Systemic Inflammatory Response Syndrome (SIRS)</measure>
    <time_frame>30 days</time_frame>
    <description>SIRS was defined as presence of at least two following parameters for a continuous period of ≥ 48 hours: body temperature &gt;38°C or &lt;36°C; heart rate &gt;90 beats per minute; hyperventilation with a respiratory rate &gt;20 breath per minute or a PaCO2 &lt; 32 mmHg; and white blood cell count &gt;12000/mm3 or &lt;4000/mm3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local complications</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic complications</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with persistent and transitory organ failure (cardiovascular, respiratory, renal)</measure>
    <time_frame>30 days</time_frame>
    <description>Marshall organ dysfunction scoring system (MODS) was used to define organ failure in the case of cardiovascular, renal and respiratory system function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical interventions</measure>
    <time_frame>30 days</time_frame>
    <description>The investigators will register the number of patients requiring surgical interventions for acute pancreatitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Imipenem group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imipenem 3 x 500 mg i.v. daily ideally for 10 days (minimum 7 days, maximum 21 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical placebo administered in identical dosage, timing and duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem</intervention_name>
    <description>A wide-spectre antibiotic from the carbapenem group</description>
    <arm_group_label>Imipenem group</arm_group_label>
    <other_name>Imipenem-cilastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>An imipenem-matching placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of acute pancreatitis defined by the Revised 2012 Atlanta Criteria

          -  first manifestation of acute pancreatitis regardless of etiology

          -  APACHE II ≥ 8 calculated within the first 24 hours of admission

          -  onset of symptoms &lt; 72 hours before admission

        Exclusion Criteria:

          -  age &lt; 18 years

          -  pregnant and breastfeeding women

          -  active and documented infection at admission

          -  concomitant antibiotic treatment or antibiotic treatment present within 72 hours
             before enrollment

          -  acute pancreatitis diagnosed at surgery

          -  active malignancy

          -  known immune deficiency

          -  patients with chronic pancreatitis

          -  patients unwilling to participate in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Davor Stimac, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gastroenterology, University Hospital Rijeka</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Rijeka</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>June 18, 2017</last_update_submitted>
  <last_update_submitted_qc>June 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Rijeka</investigator_affiliation>
    <investigator_full_name>Goran Poropat</investigator_full_name>
    <investigator_title>Postdoctoral Researcher</investigator_title>
  </responsible_party>
  <keyword>Acute pancreatitis</keyword>
  <keyword>Antibiotic prophylaxis</keyword>
  <keyword>Imipenem-cilastatin</keyword>
  <keyword>Infected pancreatic necrosis</keyword>
  <keyword>Infection</keyword>
  <keyword>Organ failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

